47 / 96
Informaciones
Psiquiátricas
2019 - n.º
236
47
al. Safety of antipychotics in people
with intelectual disability. BJP
2011;199:289-295
42. Vanlint S, Nugent M.Vitamin D and
fractures in people with intelectual
disability. J Intellect Disabil Res
2006;50:761-7
43. Schrager S. Epidemiology of osteopor-
sis in women with cognitive impair-
ment. Ment Retard 2006:44:203-11
44. Lambert TL, Farmer KC, Brahm NC.
Evaluation of Serum Prolactin Levels
in Intellectually Disbled Patients Using
Antipsychotic Medications. Int J Endo-
crinol Metab.2013:11(1)
45. de Kuijper GM, Mulderds H, Evenhuis
H, Visser F, Hoekstra PJ. Effects of
Discontinuation of Long-Term Used
Antipsychoticson Prolactin and Bone
Turnover Markers in Patients With Inte-
llectual Disability. J Clin Psychophar-
macol 2014;34(1):158-159.
46. de Kuijper G, Mulder H, Evenhuis H,
Scholte F, Visser F, Hoekstra PJ. Deter-
minants of physical health parameters
in individuals with intelectual disabi-
lity who use long-term antipsychotics.
Res Dev Disabil. 2013;34:2799–809.
47. González-Pablos E, López-Villalobos JA,
Valles-de la Calle JM, Paulino-Matos P.
[Elevation of prolactin in patients with
intellectual disability on psychophar-
macological treatment]. Semergen.
2019; 45:e6-e7. doi: 10.1016/j.
semerg.2018.10.002. Spanish.
HIPERPROLACTINEMIA INDUCIDA POR PSICOFÁRMACOS EN PERSONAS CON DISCAPACIDAD
INTELECTUAL INGRESADAS EN UN CENTRO RESIDENCIAL